Therapeutic drug monitoring of posaconazole in hematology adults under posaconazole prophylaxis: influence of food intake

[1]  D. Slain,et al.  A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis. , 2011, International journal of antimicrobial agents.

[2]  J. Gobburu,et al.  Exposure–Response of Posaconazole Used for Prophylaxis Against Invasive Fungal Infections: Evaluating the Need to Adjust Doses Based on Drug Concentrations in Plasma , 2010, Clinical pharmacology and therapeutics.

[3]  D. Lebeaux,et al.  Therapeutic Drug Monitoring of Posaconazole: a Monocentric Study with 54 Adults , 2009, Antimicrobial Agents and Chemotherapy.

[4]  G. Krishna,et al.  Tolerability and safety profile of posaconazole: evaluation of 18 controlled studies in healthy volunteers , 2009, Journal of clinical pharmacy and therapeutics.

[5]  M. Rinaldi,et al.  Posaconazole Therapeutic Drug Monitoring: a Reference Laboratory Experience , 2009, Antimicrobial Agents and Chemotherapy.

[6]  G. Krishna,et al.  Pharmacokinetics and Absorption of Posaconazole Oral Suspension under Various Gastric Conditions in Healthy Volunteers , 2008, Antimicrobial Agents and Chemotherapy.

[7]  D. Andes,et al.  Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications , 2008, Antimicrobial Agents and Chemotherapy.

[8]  O. Cornely,et al.  Pharmacokinetics of Oral Posaconazole in Neutropenic Patients Receiving Chemotherapy for Acute Myelogenous Leukemia or Myelodysplastic Syndrome , 2008, Pharmacotherapy.

[9]  Marc H Scheetz,et al.  Posaconazole: An Oral Triazole with an Extended Spectrum of Activity , 2008, The Annals of pharmacotherapy.

[10]  Patricia Muñoz,et al.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  P. Chandrasekar,et al.  Pharmacokinetics of Oral Posaconazole in Allogeneic Hematopoietic Stem Cell Transplant Recipients with Graft‐versus‐Host Disease , 2007, Pharmacotherapy.

[12]  J. Lipton,et al.  Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. , 2007, The New England journal of medicine.

[13]  J. Perfect,et al.  Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. , 2007, The New England journal of medicine.

[14]  G. Krishna,et al.  Posaconazole Plasma Concentrations in Juvenile Patients with Invasive Fungal Infection , 2007, Antimicrobial Agents and Chemotherapy.

[15]  E. Anaissie,et al.  Pharmacokinetics and Safety of Oral Posaconazole in Neutropenic Stem Cell Transplant Recipients , 2006, Antimicrobial Agents and Chemotherapy.

[16]  E. Radwanski,et al.  Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. , 2003, British journal of clinical pharmacology.

[17]  R. Courtney,et al.  Pharmacokinetics, Safety, and Tolerability of Oral Posaconazole Administered in Single and Multiple Doses in Healthy Adults , 2003, Antimicrobial Agents and Chemotherapy.

[18]  Lennart Sjöberg,et al.  Ahlstrand E , Persson L , Tidefelt U , Söderquist B. Alteration of the colonization pattern of coagulase-negative staphylococci in patients undergoing treatment for hematological malignancy. Eur J Clin Microbiol Infect Dis , 2011 .

[19]  V. Preedy,et al.  European Organization for Research and Treatment of Cancer , 2010 .

[20]  J. Perfect,et al.  Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  R. Courtney,et al.  Oral Bioavailability of Posaconazole in Fasted Healthy Subjects , 2005, Clinical pharmacokinetics.